Atovaquone/Proguanil and Metoclopramide Interaction

Understanding the Atovaquone/Proguanil and Metoclopramide Interaction

FDA-approved prescribing information for these two drugs flags their combination as a minor-severity interaction. Atovaquone/Proguanil belongs to the Antimalarial Combination class and Metoclopramide belongs to the Prokinetic / Antiemetic class - two categories that can collide when co-prescribed. The mechanism described in FDA labeling is: Metoclopramide speeds up the digestive system, which can lower the total amount of atovaquone that gets into your blood. Severity tiers matter: major flags generally advise avoidance, moderate flags often require monitoring or dose adjustment, and minor flags may only call for awareness.

Context around a specific patient determines real-world impact. Atovaquone/Proguanil has 4 total documented interactions on file in this dataset, and Metoclopramide has 23. Each additional medication compounds the interaction surface, which is why pharmacists run full-profile checks rather than evaluating one pair at a time. FDA-derived guidance for this pair is: You should only use this combination if there are no other medicines available to treat your nausea. Timing of doses, renal and hepatic function, age, and other concurrent prescriptions all shape whether a labeled interaction matters clinically.

An interaction flag is not a verdict. A large share of labeled interactions are managed routinely in clinical practice, the fix may be as simple as spacing doses or adding a monitoring test. Others require the prescriber to choose a different medication entirely. This page surfaces FDA-sourced labeling and openFDA data for educational purposes only; it is not medical advice and cannot account for your full clinical picture. Never start, stop, or adjust either Atovaquone/Proguanil or Metoclopramide based on a web page, speak with your prescriber or pharmacist before making any change.